Doha: Hamad Medical Corporation (HMC) has signed a Memorandum of Understanding (MoU) with AbbVie Biopharmaceuticals Gulf Levant to implement the Clinical Research Advancement Integrated Signature Program (CRISP) at HMC. The initiative is designed to provide clinical research professionals with access to training, certification, and professional support.
According to Qatar News Agency, AbbVie, in collaboration with the Association of Clinical Research Professionals (ACRP), will deliver a structured learning program for HMC researchers and healthcare staff. This collaboration will offer participants a structured learning pathway and the chance to earn ACRP certifications.
The training will include topics such as good clinical practice, patient safety, research ethics, protocol design, inspection readiness, and the application of new models. HMC aims to enhance the quality and impact of its clinical research through the adoption of CRISP, supporting safer, more effective treatments and improved patient outcomes.
HMC is focused on strengthening its research capacity and aligning its work with global standards. This initiative is expected to benefit patients and position Qatar as a leader in medical innovation. CRISP is set to establish new benchmarks in education, certification, and patient safety, empowering clinical research professionals to improve healthcare outcomes and elevate care standards at HMC and beyond.